About EpiBiologics
EpiBiologics is a San Mateo-based biotechnology company advancing a next-generation protein degradation pipeline that targets membrane and extracellular proteins. Its proprietary EpiTAC platform is a modular bispecific antibody system that enables tissue-specific degradation of disease-driving proteins. The company aims to develop first-in-class therapies across oncology, immunology, neurodegeneration, and metabolism.
Company details
Funding
Total raised
$180M
Last stage
Series B
Investors
Founders
Rami Hannoush
Former Genentech researcher and team leader who co-founded EpiBiologics with Jim Wells. Also served as a venture partner at Versant and partner at Mubadala Capital.
LinkedInJames Wells
Distinguished Professor at UC San Francisco whose lab pioneered the extracellular protein degradation technology (EpiTAC platform) that EpiBiologics is built upon. Previously co-founded Sunesis Pharmaceuticals.
Josef Gramespacher
Co-founder of EpiBiologics, identified across Crunchbase and Tracxn as a founding team member.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.